

A Newly Established Cell Line from Normal Human Bone Responds to $1\alpha, 25$ -Dihydroxyvitamin D_3 , Retinoic Acid and Transforming Growth Factor- β_1

Hideki CHIBA,^{1,2} Norimasa SAWADA,¹ Kousuke IBA,^{1,2}
Hiroshi ISOMURA,¹ Seiichi ISHII² and Michio MORI¹

Departments of ¹Pathology and ²Orthopedic Surgery,
Sapporo Medical University School of Medicine, S. 1, W. 17, Chuo-ku, Sapporo 060, Japan

ABSTRACT

We have recently established a new osteoblastic cell line, designated SV-HFO, from normal human bone by immortalization with simian virus 40. In the present study, we examined the effects of diffusible factors on the expression of osteoblastic phenotype in SV-HFO cell line. $1\alpha, 25$ -dihydroxyvitamin D_3 induced the expression of alkaline phosphatase (ALP) and osteocalcin. Retinoic acid down-regulated the expression of ALP, whereas it up-regulated the expression of osteocalcin. Transforming growth factor- β_1 reduced the expression of both osteoblastic properties. These effects were time- and dose-dependent. These results show that the SV-HFO cell line maintains responsiveness to these diffusible factors. This cell line is suitable model for studying both metabolism and multistep carcinogenesis of human bone.

Key words: Human osteoblasts, Simian virus 40, Cell line,
Differentiation

INTRODUCTION

Several cell lines derived from human osteosarcoma tissues have been extensively employed for study of human osteosarcomas *in vitro* (1-4), while normal human osteoblasts in culture are generally used for study of the metabolism of human bone (5-8). However, the phenotypic properties of normal human osteoblasts tend to deteriorate with increasing passage number, and the cells eventually lose their proliferative activity. Thus, immortalized osteoblastic cell lines from normal human bone have long been desired for studying the metabolism and multistep carcinogenesis of human bone.

We have recently established a human osteoblastic cell line from normal fetal bone by immortalization with simian virus 40. This cell line, designated SV-

HFO, has proliferated and has maintained its osteoblastic features even under serum-free conditions as well as under serum-supplemented conditions. These cells grew in soft agar, but did not form tumors when transplanted into athymic nude mice (9, 10). In this sense, the SV-HFO cells show intermediate properties between normal and neoplastic cells.

Transformed cells often respond abnormally to hormones or growth factors. In the present study, we examined whether the SV-HFO cells responded to major modulators of bone cells including $1\alpha, 25$ -dihydroxyvitamin D_3 ($1, 25(OH)_2D_3$), retinoic acid and transforming growth factor- β (TGF- β).

MATERIALS AND METHODS

Cell culture

The SV-HFO cells were established as described previously (9). The cells at passage 15 were seeded at a cell density of 1×10^4 cells/cm² on 100-mm culture dishes or 12-well tissue culture plates coated with $2 \mu\text{g}/\text{cm}^2$ type I collagen (Vitrogen 100; Collagen Corp., Palo Alto, CA) in serum-free Dulbecco's modified Eagle's medium (DMEM; Nissui Pharmaceutical, Tokyo, Japan) supplemented with 0.5% bovine serum albumin (Albumax; Gibco Laboratories, Grand Island, NY), ITS (containing $5 \mu\text{g}/\text{ml}$ insulin, $5 \mu\text{g}/\text{ml}$ transferrin and $5 \text{ ng}/\text{ml}$ selenious acid; Collaborative Research, Inc., Bedford, MA), 100 U/ml penicillin and $100 \mu\text{g}/\text{ml}$ streptomycin (Gibco Laboratories). These cells were cultured at 37°C in a humidified atmosphere of 5% CO_2 in air, and the medium was renewed every 3 days. To determine the effects of $1, 25(OH)_2D_3$ (Biomol Research Laboratories, Inc., Plymouth Meeting, PA), all-trans retinoic acid (RA) or TGF- β_1 (Sigma Chemical Co., St. Louis, MO) on the synthesis of ALP and osteocalcin, the cells reaching a confluent density on 12-well tissue culture plates were treated with the modulators at various concentrations for 3 consecutive days. To examine the effects of $1, 25(OH)_2D_3$, RA or TGF- β_1 on the expression of ALP and osteocalcin mRNA, the cells reaching a confluent density on 100-mm culture dishes were treated with 10^{-7}M $1, 25(OH)_2D_3$, 10^{-7}M RA or $5 \text{ ng}/\text{ml}$ TGF- β_1 for 6, 12, 24 or 48 consecutive hours. The stock solution of $1, 25(OH)_2D_3$ was in ethanol, and that of RA was in dimethyl sulfoxide (DMSO). Both test and control solutions contained the same concentration of ethanol or DMSO, which was less than 0.1%.

Measurement of ALP activity

After treatment with modulators, the cells were rinsed twice with PBS, scraped at 37°C in 0.3 ml of a solution containing 0.1% Triton X-100, 10 mM Tris-HCl (pH 7.5), 1 mM MgCl_2 and 0.02% ^{125}I - NaN_3 , and sonicated for 5 sec.

The cell extracts were centrifuged for 5 min at 10,000 g at 4°C, and kept frozen at -20°C until use.

ALP activity was spectrophotometrically measured using p-nitrophenyl-phosphate as a substrate according to the method of Lowry (11). The content of cellular protein was measured by the Pierce BCA protein assay kit (Pierce Chemical Co., Rockford, IL, USA) using BSA as a standard. ALP activity was expressed as nanomoles/minute/milligram protein.

Measurement of osteocalcin synthesis

The amount of osteocalcin secreted into the culture medium was determined by radioimmunoassay using a commercially available kit (CIS Biointernational, Gif-Sur-Yvette, France). Results were expressed as nanograms/10⁶ cells.

Northern blot analysis

Total RNAs were isolated from cell cultures using the single step thiocyanate-phenol-chloroform extraction method (12) as modified by Xie and Rothblum (13). For electrophoresis, 10 µg of total RNAs was loaded on 1% agarose gel containing 0.5 µg/ml ethidium bromide. Gels were capillary-blotted in 20× saline sodium citrate (SSC) onto nylon membranes (Hybond-N; Amersham Corp., Buckinghamshire, England) and fixed by UV light.

For the detection of ALP mRNA, membranes were prehybridized in a solution containing 50% formamide, 0.9 M NaCl, 0.1 M NaPO₄ (pH 7.4), 1% sodium dodecyl sulfate (SDS), 10 µg/ml herring sperm DNA and 5× Denhart's solution for 4h at 42°C, and then hybridized overnight at 42°C in the same solution with a ³²P-labeled cDNA probe for human ALP obtained from the American Type Culture Collection. Next, the membranes were washed twice in 2× SSC buffer containing 0.1% SDS for 5 min at room temperature and twice in 2× SSC buffer containing 1% SDS for 30 min at 68°C before exposure to film.

To identify osteocalcin mRNA, digoxigenin (DIG)-labeled RNA probe were prepared from rat cDNA using an RNA labeling kit (Boehringer Mannheim, Mannheim, Germany), and hybridization, washing and chemiluminescent detection were carried out following the DIG luminescent protocol (14).

RESULTS

Only cells reaching a confluent density were used to minimize the influence of cell proliferation on the expression of ALP and osteocalcin. In addition, to exclude the effect of serum on the expression of above mentioned proteins, the cells were cultured under the serum-free condition.

Effects of 1, 25(OH)₂D₃, RA and TGF-β₁ on ALP activity

Figure 1 shows the effects of 1, 25(OH)₂D₃ and RA on ALP activity in SV-HFO cells. Treatment of cells with 1, 25(OH)₂D₃ at concentrations higher than 10⁻⁹M for 3 days significantly induced ALP activity, with the maximal effect (3.7-fold increase) at 10⁻⁷M. In contrast, RA lowered ALP activity at concentrations higher than 10⁻⁹M. After treating cells with 10⁻⁶M RA for 3 days, the ALP activity was reduced to approximately half of the control. Addition of both 10⁻⁷M 1, 25(OH)₂D₃ and 10⁻⁷M RA resulted in a slight increase in ALP activity, but the level was significantly lower than that induced by 10⁻⁷M 1, 25(OH)₂D₃, TGF-β₁ significantly reduced ALP activity (Table I).




Fig. 1 Effects of 1, 25(OH)₂D₃ and RA on alkaline phosphatase activity in the SV-HFO cells after they reached confluency. The figures are mean values ± SD of four different wells with duplicate determinations. a), b) Significantly different from the value of the control cells cultured with 0.1% ethanol and without 1, 25(OH)₂D₃ (a) P<0.01, b) P<0.001). c), d) Significantly different from the value of the control cells cultured with 0.1% DMSO and without RA (c) P<0.05, d) P<0.01).

Effects of 1, 25(OH)₂D₃, RA and TGF-β₁ on osteocalcin production

Treatment of the cells with 1, 25(OH)₂D₃ or RA increased the amount of osteocalcin in the medium in a dose-dependent manner. The maximal effects of 1, 25(OH)₂D₃ and RA (28.5-fold and 6.5-fold, respectively) were seen at 10⁻⁷M. 1, 25(OH)₂D₃ and RA appeared to be synergistic in action in osteocalcin produc-

Table I. Effects of TGF- β_1 on alkaline phosphatase activity and the amount of osteocalcin in the SV-HFO cells after they reached confluency.

| Treatment | Alkaline phosphatase activity (nmol/min/mg protein) | Osteocalcin (ng/10 ⁶ cells) |
|---------------------------|--|---|
| None | 36.14±2.79 | 0.32±0.12 |
| TGF- β_1 0.05 ng/ml | 36.14±1.82 | 0.36±0.13 |
| 0.5 ng/ml | 30.95±2.58 ^{a)} | 0.27±0.08 |
| 5 ng/ml | 25.73±3.12 ^{b)} | 0.06±0.07 ^{a)} |

The figures are mean values \pm SD of four different wells with duplicate determinations. a), b) Significantly different from the value of the control cells cultured without TGF- β_1 (a) $P < 0.05$, b) $P < 0.01$).




Fig. 2 Effects of 1, 25(OH)₂D₃ and RA on the amount of osteocalcin in the SV-HFO cells after they reached confluency. The figures are mean values \pm SD of four different wells with duplicate determinations. a), b) Significantly different from the value of the control cells cultured with 0.1% ethanol and without 1, 25(OH)₂D₃ (a) $P < 0.01$, b) $P < 0.001$). c), d) Significantly different from the value of the control cells cultured with 0.1% DMSO and without RA (c) $P < 0.001$, d) $P < 0.05$). e) Significantly different from the value of the control cells cultured with 0.1% ethanol or 0.1% DMSO and without 1, 25(OH)₂D₃ and RA ($P < 0.001$).

tion (Fig. 2). TGF- β_1 significantly suppressed osteocalcin synthesis at 5 ng/ml (Table I). TGF- β_1 also reduced 1, 25(OH)₂D₃- or RA-induced osteocalcin pro-

duction (data not shown).

Effects of $1, 25(OH)_2D_3$, RA and TGF- β_1 on the expression of ALP and osteocalcin mRNA

We further examined the changes in the expression of ALP and osteocalcin mRNA in SV-HFO cells treated with $10^{-7}M$ $1, 25(OH)_2D_3$, $10^{-7}M$ RA or 5 ng/ml TGF- β_1 (Figs. 3 and 4).




Fig. 3 Northern blot analysis of the transcripts of genes of ALP and osteocalcin after treating confluent SV-HFO cells with $10^{-7}M$ $1, 25(OH)_2D_3$, $10^{-7}M$ RA or 5 ng/ml TGF- β_1 . The bottom panel shows ethidium bromide stain of the filter corresponding to 28S ribosomal RNA.




Fig. 4 Northern blot analysis of the transcripts of genes of ALP and osteocalcin 6 hours after treating confluent SV-HFO cells with $10^{-7}M$ $1, 25(OH)_2D_3$, $10^{-7}M$ RA, or a combination of the two. The bottom panel shows ethidium bromide stain of the filter corresponding to 28S ribosomal RNA.

The expression of ALP mRNA was up-regulated by 10^{-7} M $1, 25(\text{OH})_2\text{D}_3$ in a time-dependent manner for at least 48 hours, with a maximal increase at 6 hours. In contrast, the expression was down-regulated by 10^{-7} M RA, with the lowest value at 6 hours. The expression was also decreased by treating the cells with 5 ng/ml TGF- β_1 for 24 to 48 hours.

The expression of osteocalcin mRNA was significantly increased by treating the cells with 10^{-7} M $1, 25(\text{OH})_2\text{D}_3$ or 10^{-7} M RA, which reached the maximum at 6 hours after treatment. The effect of $1, 25(\text{OH})_2\text{D}_3$ was much greater than that of RA, and both modulators acted in a synergistic manner to osteocalcin expression. On the other hand, TGF- β_1 did not enhance the expression. $1, 25(\text{OH})_2\text{D}_3$, RA or TGF- β_1 modulated the expression of ALP and osteocalcin mRNA in a dose-dependent manner (data not shown).

DISCUSSION

We have recently established a cell line from normal human bone which possesses osteoblastic properties. This cell line, designated SV-HFO, was immunocytochemically positive for vimentin but negative for keratin and epithelial membrane antigen, which suggested that it was of mesenchymal origin. Phase-contrast microscopic and electron microscopic observations supported the mesenchymal nature of these cells. Osteoblastic nature was indicated by evidence showing that the cells produced ALP and osteocalcin (9). ALP activity in SV-HFO cells increased with increase in cell density. Osteocalcin, a bone specific protein produced by mature osteoblasts (15,16), was not induced in the cells at sparse or subconfluent density, but became detectable in the cells after they reached confluency (10).

In the present experiments, we further examined the responsiveness of SV-HFO cells to $1, 25(\text{OH})_2\text{D}_3$, RA and TGF- β_1 using ALP and osteocalcin as a marker. To minimize the influence of cell proliferation, we used the cells only after they had reached a confluent cell density. The expression of ALP in SV-HFO cells was enhanced by $1, 25(\text{OH})_2\text{D}_3$, but suppressed by either RA or TGF- β_1 . It was also shown that the expression of osteocalcin was up-regulated by $1, 25(\text{OH})_2\text{D}_3$ or RA, but down-regulated by TGF- β_1 . These effects were dose- and time-dependent.

Reduced expression of ALP by RA treatment was also observed in cultured normal human osteoblastic cells (17; Chiba *et al.*, unpublished data). These findings are inconsistent with some previous reports which showed that RA treatment induces ALP expression in rodent osteoblast-like and undifferentiated mesenchymal cells (18-21). To achieve function, steroids and related hormones must bind to their receptors complex to responsive elements in target genes (22-

26). Although the mechanism of transcriptional repression by steroids hormones remains obscure, Demay *et al.* have recently reported that there is a down-regulatory 1, 25(OH)₂D₃ responsive element which differs from the up-regulatory one, both in sequence composition and in its requirement for particular cellular factors (27). From this viewpoint, our observations seem to mean that the human ALP gene has the down-regulatory RA responsive element, while the rodent ALP gene contains the up-regulatory one.

The inhibitory effect of TGF- β_1 on ALP expression is consistent with the results obtained from primary culture and cell lines derived from "normal bones" of rodents (28-32), but not with those observed in cell lines derived from rat and human "osteosarcomas" (33-35). Thus, SV-HFO cells are considered to maintain normal responsiveness to 1, 25(OH)₂D₃, RA and TGF- β_1 at least the expression of ALP and osteocalcin is concerned. We have also observed that the cells have a potential to form mineralized tissues *in vitro*, which suppressed by RA or TGF- β_1 (in preparation). These results show that this cell line is a new model for elucidating not only multistep carcinogenesis but also metabolism of human bone.

ACKNOWLEDGMENTS

We are grateful to Dr. S. Nomura (Osaka University Medical School, Suita, Japan), for osteocalcin cDNA. This work was supported by Grants-in-Aid for Scientific Research and Cancer Research from the Ministry of Education, Science and Culture, from the Ministry of Health and Welfare, Japan, and from the Hokkaido Geriatrics Research Institute.

REFERENCES

1. FOGH J and TREMPER G. New human tumor cell lines. In: Fogh J, editor. Human tumor cell lines *in vitro*. New York, Plenum Press, 1975, 115-159.
2. FRANCESCHI RT, JAMES WM, ZERLAUTH G. 1 α , 25-dihydroxyvitamin D₃ specific regulation of growth, morphology and fibronectin in a human osteosarcoma cell line. *J Cell Physiol* 1985, 123: 401-409.
3. RODAN SG, IMAI Y, THIEDE MA, WESOLOWSKI G, THOMPSON D, BAR-SHAVIT Z, SHULL S, MANN K, RODAN GA. Characterization of a human osteosarcoma cell line (SAOS-2) with osteoblastic properties. *Cancer Res* 1987, 47: 4961-4966.
4. FOURNIER B, PRICE PA. Characterization of a new human osteosarcoma cell line OHS-4. *J Cell Biol* 1991, 114: 577-583.
5. ROBEY PG, TERMINE JD. Human bone cells *in vitro*. *Calcif Tissue Int* 1985, 37: 453-460.
6. KOSHIHARA Y, KAWAMURA M, ODA H, HIGAKI S. *In vitro* calcification in human osteoblastic cell line derived from periosteum. *Biochem Biophys Res Commun* 1987, 145: 651-657.

7. OLIVA A, MARRONE G, PAGIONE, FD, RICCIO V, PALUMBO R, ROSSANO F, ZAPPIA V. Isolation and characterization of human embryonic osteoblasts. *Calcif Tissue Int* 1992, 51: 356-362.
8. BERESFORD J, GRAVES SE, SMOOTHY CA. Formation of mineralized nodule by bone derived cells in vitro: A model of bone formation? *Am J Med Genet* 1993, 45: 163-178.
9. CHIBA H, SAWADA N, ONO T, ISHII S, MORI M. Establishment and characterization of an SV40-immortalized osteoblastic cell line from normal human bone. *Jpn J Cancer Res* 1993, 84: 290-297.
10. CHIBA H, SAWADA N, OYAMADA M, KOJIMA T, NOMURA S, ISHII S, MORI M. Relationship between the expression of the gap junction protein and osteoblast phenotype in a human osteoblastic cell line during cell proliferation. *Cell Struct Funct*, 1993, 18: 419-426.
11. LOWRY OH. Micromethods for the assay of enzyme II. Specific procedures. Alkaline phosphatase. *Methods Enzymol* 1955, 4: 371-372.
12. CHOMCZYNSKI P, SACCHI N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987, 162: 156-159.
13. XIE W, ROTHBLUM LI. Rapid, small-scale RNA isolation from tissue culture cells. *Bio Techniques* 1991, 11: 325-327.
14. HÖLTKE HJ, SANGER G, KESSLER C, SCHMITZ G. Sensitive chemiluminescent detection of digoxigenin-labeled nucleic acids: a fast and simple protocol and its applications. *Bio Techniques* 1992, 12: 104-113.
15. YOON K, BUENAGA R, RODAN GA. Tissue specificity and developmental expression of rat osteopontin. *Biochem Biophys Res Commun* 1987, 148: 1129-1136.
16. LIAN J, STEWART C, PUCHACZ E, MACKOWIAK S, SHALHOUB V, COLLART D, ZAMBETTI G, STEIN G. Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. *Proc Natl Acad Sci USA* 1989, 86: 1143-1147.
17. EVANS PB, RUNNING RA, RUSSELL RGG. Studies on the interactions between retinoic acid and 1, 25(OH)₂D₃ on human bone-derived osteoblast-like cells. In: NORMAN AW, SCHAEFER K, GRIGOLEIT H-G, HERRATH DV, editors. *VITAMIN D. Molecular, cellular and clinical endocrinology*. Berlin, Walter de Gruyter and Co, 1988, 606-607.
18. HEATH JK, RODAN SB, YOON K, RODAN GA. Rat calvarial cell lines immortalized with SV-40 large T antigen: Constitutive and retinoic acid-inducible expression of osteoblastic features. *Endocrinology* 1989, 124: 3060-3068.
19. KATAGIRI T, YAMAGUCHI A, IKEDA T, YOSHIKI S, WOZNEY JM, ROSEN V, WANG EA, TANAKA H, OMURA S, SUDA T. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. *Biochem Biophys Res Commun* 1990, 172: 295-299.
20. NAKAYAMA Y, TAKAHASHI K, NOJI S, MUTO K, NISHIJIMA K, TANIGUCHI S. Functional modes of retinoic acid in mouse osteoblastic clone MC3T3-E1, proved as a target cell for retinoic acid. *FEBS Lett* 1990, 261: 93-96.
21. RESSE DH, LARSEN RA, HORNICEK FJ. Control of alkaline phosphatase activity in C3H10T1/2: Role of retinoic acid and cell density. *J Cell Physiol* 1992, 151: 239-248.
22. EVANS RM. The steroid and steroid hormone receptor superfamily. *Science* 1988, 240: 889-895.

23. GREEN S, CHAMBON P. Nuclear receptors enhance our understanding of transcription regulation. *Trends Genet* 1988, 4: 309-314.
24. DE LUCA LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. *FASEB J* 1991, 5: 2924-2933.
25. LEID M, KASTNER P, CHAMBON P. Multiplicity generates diversity in the retinoic acid signaling pathways. *Trends Biochem Sci* 1992, 17: 427-433.
26. YU VC, NAAR AM, ROSENFELD MG. Transcriptional regulation by the nuclear receptor superfamily. *Curr Opin Biotech* 1992, 3: 597-602.
27. DEMAY MB, GERARDI JM, DELUCA HF, KRONENBERG HM. DNA sequences in the rat osteocalcin gene that bind the 1, 25-dihydroxyvitamin D₃ receptor and confer responsiveness to 1, 25-dihydroxyvitamin D₃. *Proc Natl Acad Sci USA* 1990, 87: 369-373.
28. NODA M, RODAN GA. Type- β transforming growth factor inhibits proliferation and expression of alkaline phosphatase in murine osteoblast-like cells. *Biochem Biophys Res Commun* 1986, 140: 56-65.
29. GUENTHER HL, CECCHINI MG, ELFORD PR, FLEISCH H. Effects of transforming growth factor type beta upon bone cell populations grown either in monolayer or semisolid medium. *J Bone Miner Res* 1988, 3: 269-278.
30. IBBOTSON KJ, ORCUTT CM, ANGLIN A-M, D'SOUZA SM. Effects of transforming growth factors β_1 and β_2 on a mouse clonal, osteoblastlike cell line MC3T3-E1. *J Bone Miner Res* 1989, 4: 37-45.
31. YAMAGUCHI A, KATAGIRI T, IKEDA T, WOZNEY JM, ROSEN V, WANG EA, KAHN AJ, SUDA T, YOSHIKI S. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. *J Cell Biol* 1991, 113: 681-687.
32. ELLIES LG, GUPTA AK, AUBIN JE. Differential regulation of phospholipase A₂ by cytokines inhibiting bone formation and mineralization. *Biochem Biophys Res Commun* 1992, 188: 1047-1053.
33. NODA M, RODAN GA. Type β transforming growth factor (TGF β) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. *J Cell Physiol* 1987, 133: 426-437.
34. PFEILSCHIFTER J, D'SOUZA SM, MUNDY GR. Effects of transforming growth factor- β on osteoblastic osteosarcoma cells. *Endocrinology* 1987, 121: 212-218.
35. BONEWALD LF, KESTER MB, SCHWRTZ Z, SWAIN LD, KHARE A, JOHNSON TL, LEACH RJ, BOYAN BD. Effects of combining transforming growth factor β and 1, 25-dihydroxyvitamin D₃ on differentiation of a human osteosarcoma (MG-63). *J Biol Chem* 1992, 267: 8943-8949.